JCR aiming for '15 Japanese approval of Prochymal
This article was originally published in Clinica
Executive Summary
JCR Pharmaceuticals, Osiris Therapeutics' Japanese partner for Prochymal (remestemcel-L), expects to receive local regulatory approval for the mesenchymal stem cell therapy in 2015, for the indication of graft-versus-host disease (GvHD).